CytoDyn to Present at the LD Micro Main Event XIX Investor Conference
CytoDyn (OTCQB: CYDY) announced that CFO Robert E. Hoffman will present a corporate overview at the LD Micro Main Event XIX investor conference in San Diego from October 19–21, 2025.
The presentation is scheduled for Tuesday, October 21, 2025 at 9 a.m. PDT and will be available via webcast. Topics noted include the company’s development strategy for leronlimab, a CCR5‑targeting monoclonal antibody with programs in triple‑negative breast cancer and metastatic colorectal cancer. Mr. Hoffman is available for one‑on‑one investor meetings; meeting requests go to CytoDyn@russopartnersllc.com.
CytoDyn (OTCQB: CYDY) ha annunciato che il CFO Robert E. Hoffman terrà una overview aziendale durante l'investor conference LD Micro Main Event XIX a San Diego dal 19 al 21 ottobre 2025.
La presentazione è prevista per martedì 21 ottobre 2025 alle 9:00 ora PDT e sarà disponibile in webcast. Tra gli argomenti figurano la strategia di sviluppo per leronlimab, anticorpo monoclonale diretto contro CCR5 con programmi in cancro alla mammella triplo negativo e in cancro colorettale metastatico. Il signor Hoffman è disponibile per incontri one‑to‑one con gli investitori; le richieste di riunione devono essere inviate a CytoDyn@russopartnersllc.com.
CytoDyn (OTCQB: CYDY) anunció que el CFO Robert E. Hoffman presentará una visión general de la empresa en la conferencia para inversores LD Micro Main Event XIX en San Diego del 19 al 21 de octubre de 2025.
La presentación está programada para el martes 21 de octubre de 2025 a las 9 a.m. PDT y estará disponible en webcast. Entre los temas se incluyen la estrategia de desarrollo de la compañía para leronlimab, un anticuerpo monoclonal dirigido a CCR5 con programas en cáncer de mama triple negativo y cáncer colorrectal metastásico. El señor Hoffman está disponible para reuniones individuales con inversores; las solicitudes de reuniones deben enviarse a CytoDyn@russopartnersllc.com.
CytoDyn (OTCQB: CYDY)는 CFO Robert E. Hoffman이 샌디에이고에서 열리는 투자자 회의 LD Micro Main Event XIX에서 기업 개요를 발표할 예정이라고 발표했습니다. 일정은 2025년 10월 19–21일입니다.
발표는 2025년 10월 21일 화요일 오전 9시 PDT에 예정되어 있으며 webcast로도 제공될 예정입니다. 주요 주제로는 CCR5를 표적으로 하는 단클론 항체 leronlimab의 개발 전략이 있으며 삼중음성 유방암 및 전이성 결장암에서의 프로그램이 포함됩니다. Hoffman 씨는 1대1 투자자 면담이 가능하며 면담 요청은 CytoDyn@russopartnersllc.com으로 보내주십시오.
CytoDyn (OTCQB: CYDY) a annoncé que le directeur financier Robert E. Hoffman présentera une vue d’ensemble de l’entreprise lors de la conférence pour investisseurs LD Micro Main Event XIX à San Diego du 19 au 21 octobre 2025.
La présentation est programmée pour le mardi 21 octobre 2025 à 9 h PDT et sera disponible en webcast. Les thèmes incluent la stratégie de développement de la société pour le leronlimab, un anticorps monoclonal ciblant CCR5 avec des programmes dans le cancer du sein triple négatif et le cancer colorectal métastatique. M. Hoffman est disponible pour des réunions individuels avec les investisseurs; les demandes de rendez-vous doivent être envoyées à CytoDyn@russopartnersllc.com.
CytoDyn (OTCQB: CYDY) hat bekannt gegeben, dass der CFO Robert E. Hoffman eine Unternehmensübersicht bei der Investorenkonferenz LD Micro Main Event XIX in San Diego vom 19. bis 21. Oktober 2025 präsentieren wird.
Die Präsentation ist für Dienstag, der 21. Oktober 2025 um 9:00 Uhr PDT geplant und wird als Webcast verfügbar sein. Zu den besprochenen Themen gehört die Entwicklungsstrategie für leronlimab, einen CCR5-zielenden monoklonalen Antikörper mit Programmen im dreifach negativen Brustkrebs und metastasierendem kolorektalem Krebs. Herr Hoffman steht für Einzelgespräche mit Investoren zur Verfügung; Anfragen für Meetings richten Sie bitte an CytoDyn@russopartnersllc.com.
CytoDyn (OTCQB: CYDY) أعلن أن المدير المالي Robert E. Hoffman سيعرض لمحة عن الشركة خلال مؤتمر المستثمرين LD Micro Main Event XIX في سان دييغو من 19 إلى 21 أكتوبر 2025.
من المقرر أن تكون العرض التقديمي الثلاثاء 21 أكتوبر 2025 الساعة 9:00 صباحًا بتوقيت المحيط الهادئ الصيفي وسيكون متاحًا عبر البث المباشر. تشمل المواضيع استراتيجية تطوير الشركة لـleronlimab، وهو جسم مضاد أحادي النسيلة يستهدف CCR5 مع برامج في سرطان الثدي ثلاثي السلبي وسرطان القولون والمستقيم النقيلي. السيد Hoffman متاح للاجتماعات الفردية مع المستثمرين؛ يرجى إرسال طلبات الاجتماعات إلى CytoDyn@russopartnersllc.com.
CytoDyn (OTCQB: CYDY) 宣布首席财务官Robert E. Hoffman将在圣地亚哥举行的投资者会议LD Micro Main Event XIX上，进行公司概览，时间为2025年10月19–21日。
此次演讲定于2025年10月21日星期二太平洋夏时制上午9点进行，并将通过 webcast 提供。讨论的主题包括公司针对 CCR5 的单克隆抗体 leronlimab 的开发策略，以及在三阴性乳腺癌和转移性结直肠癌方面的计划。 Hoffman先生也可进行一对一的投资者会面；请将会面请求发送至 CytoDyn@russopartnersllc.com。
- None.
- None.
CFO Robert E. Hoffman to deliver company presentation on October 21, 2025
VANCOUVER, Washington, Oct. 09, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), announced that CFO Robert E. Hoffman will present a corporate overview at the LD Micro Main Event XIX Investor Conference from October 19 – 21, 2025 at the Hotel Del Coronado in San Diego, California.
| Presentation Date: | Tuesday, October 21, 2025 | |
| Time: | 9 a.m. PDT | |
| Register to view presentation: | Webcast Link |
Mr. Hoffman will be available for one-on-one meetings with conference attendees. To request a meeting to discuss the Company’s current development strategy and upcoming milestones, please contact CytoDyn@russopartnersllc.com.
About LD Micro
LD Micro is dedicated to being the definitive resource in the small-cap space. From its industry-recognized index and robust data to hosting some of the most influential events each year, LD Micro’s mission is to provide unparalleled access and insight for those seeking the next generation of great companies.
To learn more about LD Micro, visit:
http://www.ldmicro.com
To learn more about Freedom US Markets LLC, visit:
https://www.freedomcapmkts.com/
About CytoDyn
CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.
For more information, please visit www.cytodyn.com and follow us on LinkedIn.
Note Regarding Forward-Looking Statements
This news release may contain forward-looking statements relating to, among other things, mechanism of action, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2025, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.
Corporate Contact
CytoDyn Inc.
ir@cytodyn.com
Media Contacts
Rob Haney, Ph.D., or Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
CytoDyn@russopartnersllc.com
FAQ
When will CytoDyn (CYDY) present at LD Micro Main Event XIX?
Who from CytoDyn will present at the October 21, 2025 conference?
How can investors watch CytoDyn's (CYDY) October 21, 2025 presentation?
What topics will CytoDyn cover in the October 21, 2025 presentation?
How can investors request a one‑on‑one meeting with CytoDyn at the conference?
